BERKELEY HEIGHTS, N.J., Aug. 28, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (“CorMedix”) (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that senior management will be presenting and participating in investor meetings at upcoming investor conferences taking place in September.
Cantor Global Healthcare Conference
| Date: | September 5, 2025 |
| Time: | 8:35am Eastern |
| Format: | Fireside Chat |
| Webcast: | Link to webcast |
Morgan Stanley 23rd Annual Global Healthcare Conference
| Date: | September 10, 2025 |
| Time: | 10:45am Eastern |
| Format: | Fireside Chat |
| Webcast: | Link to webcast |
About CorMedix
CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath® (taurolidine and heparin) which was approved by the FDA on November 15, 2023. CorMedix commercially launched DefenCath® in inpatient settings in April 2024 and in outpatient settings in July 2024. CorMedix commenced clinical studies in Total Parenteral Nutrition and Pediatric patient populations in 2025 and also intends to develop DefenCath® as a catheter lock solution for use in other patient populations. For more information visit: www.cormedix.com.
Investor Contact:
Dan Ferry
Managing Director
LifeSci Advisors
This email address is being protected from spambots. You need JavaScript enabled to view it.
(617) 430-7576
| Last Trade: | US$10.18 |
| Daily Change: | 0.10 0.99 |
| Daily Volume: | 1,925,376 |
| Market Cap: | US$794.650M |
September 29, 2025 August 07, 2025 | |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
